Alzinova AB (publ) (STO:ALZ)
Sweden · Delayed Price · Currency is SEK 1.744
+0.096 (5.83%)
Jul 16, 2025, 5:23 PM CET
Alzinova AB Company Description
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden.
Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b study.
The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study.
Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden.
Alzinova AB (publ)
| Country | Sweden |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Tord Labuda |
Contact Details
Address: GoCo House Mölndal, 431 53 Sweden | |
| Website | alzinova.com |
Stock Details
| Ticker Symbol | ALZ |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0007413455 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Tord Labuda M.Sc., Ph.D. | Chief Executive Officer |
| Erik Kullgren | Chief Financial Officer |
| Dr. Anders Sandberg Ph.D. | Chief Scientific Officer |
| Sebastian Hansson | Business Development Director |